National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
Herlev, Herlev, Denmark2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Not yet recruiting | Phase 1 | 2026-07-22 | NCT07694414 | |
| Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Recruiting | Phase 1 | 2026-07-01 | NCT07501117 |